No Data
No Data
Kazia Therapeutics Ltd - Intends to consider all available options to address shortcomings and restore compliance with Nasdaq rules
Kazia Therapeutics Ltd - Intends to consider all available options to address shortcomings and restore compliance with Nasdaq rules
Express News | Kazia Therapeutics Ltd - Intends to Consider All Available Options to Resolve Deficiency and Regain Compliance With Nasdaq Rule
Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
SYDNEY, May 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) (Kazia or the company) received a letter on May 22, 2024 from Nasdaq notifying the Company that, while the Company has n
Kazia Therapeutics Says Nasdaq Determined That Company Is Eligible For Additional 180 Calendar Day Period, Or Until November 18, 2024 To Regain Compliance
On May 22, 2024, the Company received a letter from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has determined that
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersBiodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by 67.7% to $2.13 during Tuesday's pre-market session. The market value of their outstanding shares is at $9.3 million. Durect (NASDAQ:DRR
Kazia Therapeutics Shares Are Trading Lower. The Company Announced the Completion of the EVT801 Phase 1 Clinical Trial.
Kazia Therapeutics Shares Are Trading Lower. The Company Announced the Completion of the EVT801 Phase 1 Clinical Trial.